CN106511689A - Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type fallopian tube blockage - Google Patents
Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type fallopian tube blockage Download PDFInfo
- Publication number
- CN106511689A CN106511689A CN201710051061.4A CN201710051061A CN106511689A CN 106511689 A CN106511689 A CN 106511689A CN 201710051061 A CN201710051061 A CN 201710051061A CN 106511689 A CN106511689 A CN 106511689A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- root
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 230000007812 deficiency Effects 0.000 title claims abstract description 18
- 210000003101 oviduct Anatomy 0.000 title abstract description 10
- 210000003734 kidney Anatomy 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 13
- 241000258920 Chilopoda Species 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 11
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract 2
- 208000030843 hydrosalpinx Diseases 0.000 claims description 25
- 206010065789 Fallopian tube obstruction Diseases 0.000 claims description 24
- 235000021419 vinegar Nutrition 0.000 claims description 21
- 239000000052 vinegar Substances 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000576429 Forsythia suspensa Species 0.000 claims description 12
- 240000007164 Salvia officinalis Species 0.000 claims description 12
- 235000005412 red sage Nutrition 0.000 claims description 12
- 241001647745 Banksia Species 0.000 claims description 11
- 241000123589 Dipsacus Species 0.000 claims description 11
- 241000287828 Gallus gallus Species 0.000 claims description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 11
- 241000220317 Rosa Species 0.000 claims description 11
- 240000008488 Thlaspi arvense Species 0.000 claims description 11
- 235000008214 Thlaspi arvense Nutrition 0.000 claims description 11
- 244000178320 Vaccaria pyramidata Species 0.000 claims description 11
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims description 11
- 229940107666 astragalus root Drugs 0.000 claims description 11
- 210000004317 gizzard Anatomy 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 241000110637 Cuscuta chinensis Species 0.000 claims description 10
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 3
- 240000001398 Typha domingensis Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000005461 lubrication Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 230000036512 infertility Effects 0.000 abstract description 4
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 241000521257 Hydrops Species 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract 2
- 239000013589 supplement Substances 0.000 abstract 2
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 32
- 238000000034 method Methods 0.000 description 9
- 241000736199 Paeonia Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 240000000260 Typha latifolia Species 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 208000021267 infertility disease Diseases 0.000 description 6
- 208000026351 Fallopian Tube disease Diseases 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000715 Mucilage Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960003742 phenol Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 241000762515 Hydrosalpinx Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229960003666 liquefied phenol Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 230000009303 sperm storage Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Insects & Arthropods (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type fallopian tube blockage. The traditional Chinese medicine composition is prepared from 25-35 parts of radix salviae miltiorrhizae, 10-14 parts of radix paeoniae rubra, 2-4 parts of stir-baked squama manitis powder, 10-14 parts of spina gleditsiae, 10-14 parts of fructus forsythiae, 16-20 parts of herba patriniae, 0.5-1.5 parts of centipedes, 10-14 parts of semen vaccariae, 10-14 parts of fructus liquidambaris, 10-14 parts of pollen typhae, 12-18 parts of semen cuscutae, 16-20 parts of radix dipsaci asperoidis, 10-14 parts of radix bupleuri, 10-14 parts of vinegar-processed rhizoma cyperi, 16-20 parts of vinegar-processed rhizoma corydalis, 25-35 parts of radix astragali preparata, 10-14 parts of radix paeoniae alba, 10-14 parts of radix angelicae sinensis, 10-14 parts of radix aucklandiae, 10-14 parts of endothelium corneum gigeriae galli and 4-8 parts of honey-fried licorice roots. The medicinal materials selected for the traditional Chinese medicine composition are in proper compatibility and fine formulation and supplement one another in function, all the medicinal materials are used in cooperation to achieve the purposes of promoting blood circulation to remove blood stasis, dredging meridians and collaterals, strengthening body resistance to dispel pathogenic factors and promoting blood circulation to nourish the kidneys, and the traditional Chinese medicine composition has a specific treatment effect on sterility caused by fallopian tube blockage or fallopian tube hydrops of women; all the medicinal materials restrict and supplement one another in medicinal property, and the traditional Chinese medicine composition has few toxic or side effects and is safe to take.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, and in particular to a kind of Chinese traditional medicine composition for treating blood stasis renal deficiency type fallopian tube obstruction
Thing.
Background technology
Infertility is the common disease of gynaecology, and its Important cause of disease is the fallopian tube obstruction that salpingitis tubal causes.It is reported that, because
Tubal factor causes the infertile 30%-50% for accounting for infertility of the women of child-bearing age.Fallopian tubal is the main composition of female reproductive system
One of part, with conveying sperm, ovum and embryonated egg and offer sperm Storage, capacitation, acrosome reaction and fertilization place etc.
Physiological function.Fallopian tubal fine structure, easily damages.The cause of disease is more to make fallopian tubal attach to other adjacent tissues based on inflammation,
And cause fallopian tubal to damage deformation, or reduce oviducal activity.Therefore, the blocking barrier at any position of fallopian tubal all may
Cause Tubal Function of Sterility obstacle and cause infertile.
At present, operative treatment being adopted western medical treatment fallopian tube obstruction more, there is accurate positioning, determined curative effect；But
There is the fallopian tube adhesion easily deficiency such as recurrence after expensive, treatment in western medical treatment.The traditional Chinese medical science thinks this disease category " extravasated blood illness ", disease
Because the invasion of damaged by excess of seven emotions, qi depression to blood stasis, exopathogen, cold solidifying stasis blocking, heat symptoms caused by an exopathgen blood clotting, dampness and heat stasis, kidney deficiency blood stasis etc., pathogenesis
Stagnant with the stasis of blood relevant, stagnation of blood stasis uterus, QI-blood circulation be not smooth, and the operation of smart ovum is obstructed, two essences can not with reference to and cause infertile.But
In the concrete practice of Chinese traditional treatment fallopian tube obstruction, its dialectical viewpoint for treating but differs, some treat from liver, strengthens promoting blood circulation
The product of disperse blood stasis and dredge collateral, while strong regulating spirit and emotion by oneself is dredged；Have using promoting blood circulation, warming channel and expelling cold, swelling and pain relieving as the principles of formulating prescriptions；
Have then using clearing heat and promoting diuresis, promoting blood circulation and removing obstruction in channels as the principles of formulating prescriptions；Prescription is carried out according to above-mentioned different treatment thoughts, which is to defeated ovum
The obstructed therapeutic effect of pipe differs greatly；And be directed to for the selection of each bulk drug and the allotment of compatibility relationship lack in prescription
Property, it is simply will to be combined with medicine the effects such as beneficial gas, promoting blood circulation, stagnation resolvation, dredging collateral mostly, therefore, great majority treatment is defeated
The curative effect of the obstructed Chinese medicine of oviduct is still unsatisfactory, or even some drugs on patients's bodies also have certain side effect.
The content of the invention
For above-mentioned prior art, it is an object of the invention to provide a kind of Chinese medicine for treating blood stasis renal deficiency type fallopian tube obstruction
Composition.
For achieving the above object, the present invention adopts following technical proposals：
A kind of first aspect present invention, there is provided Chinese medicine composition for treating blood stasis renal deficiency type fallopian tube obstruction, its raw material group
Become：
Red sage root 25-35 parts, radix paeoniae rubrathe 10-14 parts, stir-baked SQUAMA MANITIS powder 2-4 parts, spina gleditsiae 10-14 parts, capsule of weeping forsythia 10-14 parts, Patrinia scaniosaefolia
Careless 16-20 parts, centipede 0.5-1.5 parts, seed of cowherb 10-14 parts, play both sides of the street 10-14 parts, cattail pollen 10-14 parts, seed of Chinese dodder 12-18
Part, dipsacus root 16-20 part, radix bupleuri 10-14 parts, prepared RHIZOMA CYPERI with vinegar 10-14 parts, vinegar corydalis tuber 16-20 parts, astragalus root 25-35 parts, the root of herbaceous peony
10-14 parts, Radix Angelicae Sinensis 10-14 parts, banksia rose 10-14 parts, the membrane of a chicken's gizzard 10-14 parts, honey-fried licorice root 4-8 parts.
The Chinese medicine composition of the treatment blood stasis renal deficiency type fallopian tube obstruction of the present invention, preferred prescription is：
30 parts of the red sage root, 12 parts of the radix paeoniae rubrathe, 3 parts of stir-baked SQUAMA MANITIS powder, 12 parts of spina gleditsiae, 12 parts of the capsule of weeping forsythia, 18 parts of field pennycress, 1 part of centipede,
12 parts of the seed of cowherb, plays both sides of the street 12 parts, 12 parts of cattail pollen, 15 parts of the seed of Chinese dodder, 18 parts of dipsacus root, 12 parts of radix bupleuri, 12 parts of prepared RHIZOMA CYPERI with vinegar, and vinegar prolongs
18 parts of Hu rope, 30 parts of astragalus root, 12 parts of the root of herbaceous peony, 12 parts of Radix Angelicae Sinensis, 12 parts of the banksia rose, 12 parts of the membrane of a chicken's gizzard, 6 parts of honey-fried licorice root.
The compatibility mechanism of Chinese medicine composition of the present invention：It is with the red sage root, the radix paeoniae rubrathe, stir-baked SQUAMA MANITIS as monarch drug in a prescription, promoting blood circulation and removing blood stasis, tonneau Jing
Network, dredging punching appoint qi and blood, and radix paeoniae rubrathe energy clearing heat and cooling blood, the anti-stasis of blood to change heat long.Field pennycress, the capsule of weeping forsythia, spina gleditsiae eliminating dampness and heat, removing toxic substances disappear
It is swollen, the residual poison in removing summer-heat blood；The flat kidney tonifying gas of the seed of Chinese dodder, dipsacus root, astragalus root beneficial gas, Chinese angelica blood supplementing promoting circulation of blood take strengthening vital QI to eliminate pathogenic factors, promoting blood circulation
The effect of kidney tonifying, is for ministerial drug.Centipede, the seed of cowherb, play both sides of the street, Pollen Typhae degrading the channel, sharp blood vessels strengthen power promoting blood circulation and removing blood stasis；
Radix bupleuri, rhizoma cyperi, the root of herbaceous peony, vinegar corydalis tuber liver-smoothing, qi-regulating, soft liver pain relieving, the banksia rose, the membrane of a chicken's gizzard regulating qi-flowing for harmonizing stomach, all medicines are all adjutant；Process
Radix Glycyrrhizae is to make, coordinating the drug actions of a prescription.
The present invention for blood stasis renal deficiency type fallopian tube obstruction carry out it is dialectical treat, kinds of traditional Chinese medicines is carried out into compatibility, medicine it
Between played jointly promoting blood circulation and removing blood stasis, tonneau channels and collaterals, strengthening vital QI to eliminate pathogenic factors, the effect of blood-activating kidney-tonifying, with obvious synergistic effect, fully
The compatibility relationship that mutual reinforcement between mutually makes is played.
In side, selected medicinal material compatibility is suitable, and refining formula functionally complements each other, and with promoting blood circulation and removing blood stasis, tonneau channels and collaterals, helps
For the purpose of positive eliminating evil, blood-activating kidney-tonifying, all medicines are used cooperatively, and what women fallopian tube obstruction, hydrops etc. were caused infertile has
Targetedly curative effect；All medicines are mutually made in the property of medicine and are mutually helped, and toxicity is few, take safety.
In the Chinese medicine composition of the treatment blood stasis renal deficiency type fallopian tube obstruction of the present invention, each raw material components are one organic
It is overall, it is indispensable.Inventor had found in R＆D process, reduces any one of above-mentioned composition raw material components, or with
Bulk drug with the similar property of medicine is replaced to the raw material components of Chinese medicine composition of the present invention, then the overall work of Chinese medicine composition
Reduced with effect is significant；Other raw material components are further added by the basis of the Chinese medicine composition of the present invention, Chinese medicine composition
Whole structure does not improve significantly, or even the situation that the whole structure for having Chinese medicine composition is reduced occurs.
Each raw material can be added water to cook by the Chinese medicine composition of above-mentioned treatment blood stasis renal deficiency type fallopian tube obstruction, make decoction；
Can also prepare according to additive method.In a specific embodiment of the present invention, above-mentioned treatment blood stasis renal deficiency type fallopian tubal
The preparation method of obstructed Chinese medicine composition is：
(1) by cattail pollen gauze wrapped, then with the red sage root, the radix paeoniae rubrathe, spina gleditsiae, the capsule of weeping forsythia, field pennycress, the seed of cowherb, play both sides of the street,
The seed of Chinese dodder, dipsacus root, radix bupleuri, prepared RHIZOMA CYPERI with vinegar, vinegar corydalis tuber, astragalus root, the root of herbaceous peony, Radix Angelicae Sinensis, the banksia rose, the membrane of a chicken's gizzard, honey-fried licorice root mixing, add water
Decoct twice, filtration (adds 8-10 times for the first time and measures water, decoct 30-60 minutes；Add 6-8 times for second and measure water, decoct 20-40 point
Clock), merging filtrate；
(2) fry centipede micro- to shortcake, it is finely ground, then it is added in the filtrate of step (1) in the lump with stir-baked SQUAMA MANITIS powder, mixing is equal
It is even, obtain final product.
Traditional Chinese medicine ingredients are complicated, existing water soluble ingredient in a kind of medicinal material, have oil-soluble or Alcohol soluble composition, and some work again
Property composition easily inactivate at high temperature, therefore Effective Component of Chinese Medicine is carried out by selecting suitable extracting method and extraction process
Extract and separate, active ingredient can be extracted to greatest extent and ensure the activity of active ingredient, so as to ensure the clinic of product
Effect.
Experiment proves that, using above-mentioned preparation method, can extract to greatest extent in Chinese medicine composition it is effective into
Divide and ensure the activity of active ingredient, so as to ensure the clinical effectiveness of product.
Application of the above-mentioned Chinese medicine composition in the pharmaceutical preparation for preparing treatment blood stasis renal deficiency type fallopian tube obstruction is also this
The scope of invention protection.
Second aspect present invention, there is provided a kind of pharmaceutical preparation for treating blood stasis renal deficiency type fallopian tube obstruction, by above-mentioned Chinese medicine
Composition and pharmaceutically acceptable auxiliary material are prepared from.
Said medicine preparation can make various pharmaceutical dosage forms, such as pill, capsule, tablet, powder, granule or oral
Liquid etc..
The pharmaceutically acceptable auxiliary material is the customary adjuvant in pharmaceutical preparation, such as：Disintegrant, lubricant, binder
Deng；One or more preferably in glycerine, butanediol, trehalose, glycine betaine, starch, sodium carboxymethylcellulose.
Effect of the Chinese medicine composition or pharmaceutical preparation of the present invention：Dredging collateral and promoting blood circulation, blood-activating analgetic, tonifying kidney.Cure mainly blood
Stasis of blood nephrasthenia syndrome.Card sees below abdomen pendant pain or shouting pain, and waist sacrum aches, and Jing row waist abdomen pain increases, profuse leukorrhea, Se Bai or Huang, Jing rows
Color is dim block, and spiritlessness and weakness, complexion are dark dim；Tongue nature is dim or has ecchymosis petechia, and tongue is thin white, and deeptensepulse is puckery.It is adapted to fallopian tube obstruction,
After hydrosalpinx, pelvic adhesion or palace laparoscopy etc., and see above-mentioned all card persons.
Beneficial effects of the present invention：
Medicinal material compatibility selected by the Chinese medicine composition of the present invention is suitable, and refining formula functionally complements each other, with promoting blood circulation
For the purpose of the stasis of blood, tonneau channels and collaterals, strengthening vital QI to eliminate pathogenic factors, blood-activating kidney-tonifying, all medicines are used cooperatively, and women fallopian tube obstruction, hydrops etc. are caused
It is infertile with targetedly curative effect；All medicines are mutually made in the property of medicine and are mutually helped, and toxicity is few, take safety.
Specific embodiment
Below by instantiation, the present invention will be further elaborated, it should explanation, the description below be only for
The present invention is explained, its content is not defined.
Embodiment 1：
Formula：30 grams of the red sage root, 12 grams of the radix paeoniae rubrathe, 3 grams of stir-baked SQUAMA MANITIS powder, 12 grams of spina gleditsiae, 12 grams of the capsule of weeping forsythia, 18 grams of field pennycress, Wu
1 gram of centipede, 12 grams of the seed of cowherb play both sides of the street 12 grams, 12 grams of cattail pollen, 15 grams of the seed of Chinese dodder, 18 grams of dipsacus root, 12 grams of radix bupleuri, prepared RHIZOMA CYPERI with vinegar 12
Gram, 18 grams of vinegar corydalis tuber, 30 grams of astragalus root, 12 grams of the root of herbaceous peony, 12 grams of Radix Angelicae Sinensis, 12 grams of the banksia rose, 12 grams of the membrane of a chicken's gizzard, 6 grams of honey-fried licorice root.
Preparation method：
(1) by cattail pollen gauze wrapped, then with the red sage root, the radix paeoniae rubrathe, spina gleditsiae, the capsule of weeping forsythia, field pennycress, the seed of cowherb, play both sides of the street,
The seed of Chinese dodder, dipsacus root, radix bupleuri, prepared RHIZOMA CYPERI with vinegar, vinegar corydalis tuber, astragalus root, the root of herbaceous peony, Radix Angelicae Sinensis, the banksia rose, the membrane of a chicken's gizzard, honey-fried licorice root mixing, add water
Decoct twice, filtration (adds 10 times of amount water for the first time, decocts 40 minutes；Second plus 8 times of amount water, decoct 30 minutes), merge filter
Liquid；
(2) fry centipede micro- to shortcake, it is finely ground, then it is added in the filtrate of step (1) in the lump with stir-baked SQUAMA MANITIS powder, mixing is equal
It is even, obtain final product.
Orally take, the daily morning and evening twice, 15 days is a course for the treatment of.
Embodiment 2：
Formula：25 grams of the red sage root, 14 grams of the radix paeoniae rubrathe, 2 grams of stir-baked SQUAMA MANITIS powder, 14 grams of spina gleditsiae, 10 grams of the capsule of weeping forsythia, 20 grams of field pennycress, Wu
0.5 gram of centipede, 14 grams of the seed of cowherb play both sides of the street 10 grams, 14 grams of cattail pollen, 12 grams of the seed of Chinese dodder, 20 grams of dipsacus root, 10 grams of radix bupleuri, prepared RHIZOMA CYPERI with vinegar
14 grams, 16 grams of vinegar corydalis tuber, 35 grams of astragalus root, 10 grams of the root of herbaceous peony, 14 grams of Radix Angelicae Sinensis, 10 grams of the banksia rose, 14 grams of the membrane of a chicken's gizzard, 4 grams of honey-fried licorice root.
Preparation method is with embodiment 1.
Embodiment 3：
Formula：35 grams of the red sage root, 10 grams of the radix paeoniae rubrathe, 4 grams of stir-baked SQUAMA MANITIS powder, 10 grams of spina gleditsiae, 14 grams of the capsule of weeping forsythia, 16 grams of field pennycress, Wu
1.5 grams of centipede, 10 grams of the seed of cowherb play both sides of the street 14 grams, 10 grams of cattail pollen, 18 grams of the seed of Chinese dodder, 16 grams of dipsacus root, 14 grams of radix bupleuri, prepared RHIZOMA CYPERI with vinegar
10 grams, 20 grams of vinegar corydalis tuber, 25 grams of astragalus root, 14 grams of the root of herbaceous peony, 10 grams of Radix Angelicae Sinensis, 14 grams of the banksia rose, 10 grams of the membrane of a chicken's gizzard, 8 grams of honey-fried licorice root.
Preparation method is with embodiment 1.
Embodiment 4：
Filtrate after embodiment 1 is decocted is prepared into capsule in conventional manner, and specification is 0.25g/ grains.
Embodiment 5：
Filtrate after embodiment 1 is decocted is prepared into pill in conventional manner.
Embodiment 6：
Filtrate after embodiment 1 is decocted is prepared into granule in conventional manner.
Comparative example 1：
The present inventor the multi-flavor bulk drug with the close property of medicine has been carried out in R＆D process compatibility relationship investigation and
The research of drug effect, as a result finds, even if similar but different from other the bulk drug compatibility of the property of medicine between a few taste bulk drugs makes
With rear, its effect significant difference.
For example：With radix bupleuri, Radix Angelicae Sinensis, the radix paeoniae rubrathe, pangolin, the root bark of tree peony are processed, the seed of cowherb, spina gleditsiae, dandelion, played both sides of the street, lost
Sauce grass, Fructus Aurantii, dipsacus root, radix cyathulae, Radix Glycyrrhizae carry out prescription.
Fallopian tube disease rat model is set up in conventional manner, investigates the Chinese medicine of the embodiment of the present invention 1 and comparative example 1
Therapeutic effect of the composition to fallopian tube obstruction, animal experiment show, the Chinese medicine composition of the embodiment of the present invention 1 to fallopian tubal not
Logical therapeutic effect will be significantly better than comparative example 1.Illustrate that the composition of the present invention meets the compatibility relationship of Chinese medicine, between each component
With collaboration facilitation, it is not the simple replacement or combination of the bulk drug with the similar property of medicine.
Comparative example 2：
In Chinese medicine composition, the dose of each bulk drug is the mark efficacy of a drug, even if the medicine composition of prescription is identical, if but medicine
The consumption of thing is different, its efficacy of a drug then have size point, compatibility relationship then has the change of monarch, so as to its work(cure mainly it is then each
It is different.The present inventor has carried out grinding for investigation and drug effect in R＆D process to the content of each raw material in Chinese medicine composition
Study carefully, as a result find, the difference of inappropriate raw material proportioning relation, especially monarch drug in a prescription and deal shared by ministerial drug, its effect are poor
It is not notable.For example：By the consumption of the red sage root in embodiment 1 be adjusted to 40 grams, the consumption of the radix paeoniae rubrathe be adjusted to 5 grams, the consumption of stir-baked SQUAMA MANITIS
Be adjusted to 5 grams, the consumption of field pennycress be adjusted to 25 grams, the consumption of the capsule of weeping forsythia be adjusted to 5 grams, the consumption of spina gleditsiae be adjusted to 18 grams,
The consumption of other raw materials is with embodiment 1, and prepares as described in Example 1.
Fallopian tube disease rat model is set up in conventional manner, investigates the Chinese medicine of the embodiment of the present invention 1 and comparative example 2
Therapeutic effect of the composition to fallopian tube obstruction, animal experiment show, the Chinese medicine composition of the embodiment of the present invention 1 to fallopian tubal not
Logical therapeutic effect will be significantly better than comparative example 2.In illustrating the composition of the present invention, the consumption of each bulk drug is not conventional
Adjustment institute is getable, and in the Chinese prescription of the present invention, the consumption proportion of each raw medicinal material is according to its character of medicinal material, Jun Chenzuo
Make what the various Considerations such as compatibility were determined, for the overall drug effect of Chinese medicine composition plays very important effect.
Animal experiment：
1. impact of the Chinese medicine composition of the present invention to fallopian tube disease rat model tubal patency situation
(1) test method：
1) animal model：
With Wistar rats (female, 4-6 week old, 180～200g of body weight, cleaning grade) for experimental animal, with reference to " uterus is big
Mouse method " after anaesthetizing 10～15 minutes, is cut off belly wool, is disappeared with the tincture of iodine, alcohol with yellow Jackets (25mg/kg) lumbar injection
Poison, opens abdominal cavity, injects 20% Hydroxybenzene mucilage, sewing-up cut respectively in uterus at fallopian tubal into two oviductus lateralis；
Wherein, 20% Hydroxybenzene mucilage compound method is：Liquefied phenol 5ml, Arabic gum 1g, glycerine 4ml, plus distilled water is extremely
25ml, is tuned into paste, injects 0.04ml.
2) test packet and administration：
Wistar rats are randomly divided into into Normal group (sham-operation group) 10 and modeling group 50.Modeling group is postoperative again
5 groups are randomly divided into, 10 per group, respectively model control group, positive drug group, the basic, normal, high dosage of Chinese medicine composition of the present invention
Group.Postoperative 2nd day beginning gastric infusion, gavage volume 10ml/kg, continuous 35 days.
Wherein, Normal group and model control group gavage distilled water；The basic, normal, high dosage group of Chinese medicine composition of the present invention
Difference gavage Chinese medicine composition (prepared by embodiment 1) of the present invention, respectively：Low dose group 6g crude drug/kg.d, middle dose group 12g
Crude drug/kg.d, high dose group 24g crude drug/kg.d are respectively equivalent to 4 times, 8 times and 16 times of clinical usual amounts；Positive drug group
Gavage PENYANJING KELI, dosage are 3g/ (kg d) (equivalent to taking 20 times of dosage clinical days) administration.Gavage was put to death after 35 days
Rat, from uterus to fallopian tubal, injection dilution methylene blue solution, checks tubal patency situation.
(3) result of the test：
Result of the test is shown in Table 1.
Table 1：
As can be seen from Table 1, model control group rat tubal patency number of cases is substantially reduced compared with Normal group, is had significantly
Sex differernce (P ＜ 0.01), illustrates that 20% Hydroxybenzene mucilage 0.04ml of injection can cause fallopian tube disease in two oviductus lateralis.It is positive
The basic, normal, high dosage group rat tubal patency number of cases of medicine group, Chinese medicine composition of the present invention has increasing compared with model control group
Plus, illustrate the defeated ovum of positive drug (PENYANJING KELI) and Chinese medicine composition of the invention to fallopian tube disease rat model
Pipe is unobstructed effect；Compared with positive drug group, the middle dose group and high dose group of Chinese medicine composition of the present invention is to rat model
Oviducal dredging action effect is more notable.
Safety testing：
(1) acute toxicity test：
By the Chinese medicine composition of the present invention with Cmax, maximum volume gastric infusion, the successive administration 3 times in the 24h, often
Minor tick 4h, accumulation medicine total amount reach 30g/kg.After administration in 7 days, mouse activity, feed, excretion are normal, well-grown,
Hair color light, its average weight increase with the prolongation of test period.8d puts to death test mice, carries out system postmortem and internal organs
Coefficient and histological examination, it is as a result without exception, show the Chinese medicine composition of the present invention without acute toxic reaction.
(2) long term toxicity test：
The Chinese medicine composition of the present invention is divided into into 5.0g (crude drug)/kg/ days, (lifes of 10.0g (crude drug)/kg/ days and 15.0g
Medicine)/kg/ days three dosage groups, after continuous gavage is administered 2 months, test mice is put to death, determine indices.Observation and measure
Project is included such as outward appearance Signs and behavioral activity, secretion, fecal character；The conventional index and biochemical indicator of blood；System corpse
The content such as inspection and organ coefficient and histological examination.
As a result show：Mouse continuous oral is given with various dose, on the food-intake and body weight increase of mouse without impact.It is right
Hepatic and renal function does not find that overt toxicity is acted on；Illustrate the Chinese medicine composition safety non-toxic of the present invention.
Clinical testing：
1. research object
May 2014 May in 2012 fallopian tube obstruction patient 120 to hospital is chosen, patient that will be selected is random
It is divided into treatment group and control group, 60 per group.Age for the treatment of group and control group, course of disease etc. without significant (p ＞ 0.05),
With comparativity.
2. diagnostic method：By celioscopy, the oviducal patency of clinical evaluation.
3. treatment method：
Decoction prepared by the oral embodiment of the present invention 1 for the treatment of group, twice daily, sooner or later respectively once, 15 days is a course for the treatment of.
The oral PENYANJING KELI of control group, by specification are taken, and are within 15 days a course for the treatment of.
Oviducal patency is understood by Salpingography after 3 courses for the treatment of of treatment, and carries out statistical analysis.
4. criterion of therapeutical effect：
(1) cure：After treatment is completed, Jing Salpingographies are observed visible ipsilateral fallopian tube and realize unobstructed, Jing 1 year again
Follow-up patient become pregnant.
(2) effectively：After treatment is completed, Jing Salpingographies are observed the unobstructed situation of visible ipsilateral fallopian tube and are had clear improvement.
(3) it is invalid：Tubal patency degree is without being clearly better or increase.
5. result：
Treatment results are shown in Table 1.
Table 1：Treatment results
Jing X2Inspection, is compared with control group, and treatment group significantly improves (P to the treatment total effective rate of fallopian tube obstruction<
0.05), have no adverse reaction in therapeutic process example.Illustrate that the Chinese medicine composition of the present invention has clinic well to fallopian tube obstruction
Therapeutic effect, and safe without toxic side effect.
The above, the only present invention preferably specific embodiment, but protection scope of the present invention is not limited thereto,
It is any to be familiar with those skilled in the art in the technical scope of present disclosure, technology according to the present invention scheme and its invention
Design in addition equivalent or change, should all be included within the scope of the present invention.
Claims (8)
1. a kind of Chinese medicine composition for treating blood stasis renal deficiency type fallopian tube obstruction, it is characterised in that its raw material is consisted of：
Red sage root 25-35 parts, radix paeoniae rubrathe 10-14 parts, stir-baked SQUAMA MANITIS powder 2-4 parts, spina gleditsiae 10-14 parts, capsule of weeping forsythia 10-14 parts, field pennycress 16-
20 parts, centipede 0.5-1.5 parts, seed of cowherb 10-14 parts, play both sides of the street 10-14 parts, cattail pollen 10-14 parts, seed of Chinese dodder 12-18 parts, river
Disconnected 16-20 parts, radix bupleuri 10-14 parts, prepared RHIZOMA CYPERI with vinegar 10-14 parts, vinegar corydalis tuber 16-20 parts, astragalus root 25-35 parts, root of herbaceous peony 10-14
Part, Radix Angelicae Sinensis 10-14 parts, banksia rose 10-14 parts, the membrane of a chicken's gizzard 10-14 parts, honey-fried licorice root 4-8 parts.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that its raw material is consisted of：
30 parts of the red sage root, 12 parts of the radix paeoniae rubrathe, 3 parts of stir-baked SQUAMA MANITIS powder, 12 parts of spina gleditsiae, 12 parts of the capsule of weeping forsythia, 18 parts of field pennycress, 1 part of centipede, king is not
12 parts of row is stayed, 12 parts are played both sides of the street, 12 parts of cattail pollen, 15 parts of the seed of Chinese dodder, 18 parts of dipsacus root, 12 parts of radix bupleuri, 12 parts of prepared RHIZOMA CYPERI with vinegar, vinegar corydalis tuber
18 parts, 30 parts of astragalus root, 12 parts of the root of herbaceous peony, 12 parts of Radix Angelicae Sinensis, 12 parts of the banksia rose, 12 parts of the membrane of a chicken's gizzard, 6 parts of honey-fried licorice root.
3. the preparation method of the Chinese medicine composition described in claim 1 or 2, it is characterised in that step is as follows：
(1) by cattail pollen gauze wrapped, then with the red sage root, the radix paeoniae rubrathe, spina gleditsiae, the capsule of weeping forsythia, field pennycress, the seed of cowherb, play both sides of the street, Tu silks
Son, dipsacus root, radix bupleuri, prepared RHIZOMA CYPERI with vinegar, vinegar corydalis tuber, astragalus root, the root of herbaceous peony, Radix Angelicae Sinensis, the banksia rose, the membrane of a chicken's gizzard, honey-fried licorice root mixing, add water to cook
Twice, filter, merging filtrate；
(2) fry centipede micro- to shortcake, it is finely ground, then it is added in the filtrate of step (1) in the lump with stir-baked SQUAMA MANITIS powder, is well mixed,
Obtain final product.
4. preparation method as claimed in claim 3, it is characterised in that the concrete operations that decocting is boiled are：Add 8-10 times for the first time
Amount water, decocts 30-60 minutes；Add 6-8 times for second and measure water, decoct 20-40 minutes.
5. the Chinese medicine composition described in claim 1 or 2 is in the pharmaceutical preparation for preparing treatment blood stasis renal deficiency type fallopian tube obstruction
Purposes.
6. a kind of pharmaceutical preparation for treating blood stasis renal deficiency type fallopian tube obstruction, the Chinese medicine composition by described in claim 1 or 2 and
Pharmaceutically acceptable auxiliary material is prepared from.
7. pharmaceutical preparation as claimed in claim 6, it is characterised in that the pharmaceutically acceptable auxiliary material is disintegrant, profit
Lubrication prescription or binder.
8. pharmaceutical preparation as claimed in claim 6, it is characterised in that the formulation of the pharmaceutical preparation is pill, capsule, piece
Agent, powder, granule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051061.4A CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051061.4A CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511689A true CN106511689A (en) | 2017-03-22 |
| CN106511689B CN106511689B (en) | 2020-01-14 |
Family
ID=58337053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710051061.4A Active CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511689B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567871A (en) * | 2018-01-25 | 2018-09-25 | 徐光亮 | It is a kind of to treat infertile medicine pill |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949664A (en) * | 2012-11-13 | 2013-03-06 | 刘晓燕 | Traditional Chinese medicinal composite for treating fallopian-tube obstructive infertility |
-
2017
- 2017-01-23 CN CN201710051061.4A patent/CN106511689B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949664A (en) * | 2012-11-13 | 2013-03-06 | 刘晓燕 | Traditional Chinese medicinal composite for treating fallopian-tube obstructive infertility |
Non-Patent Citations (1)
| Title |
|---|
| 武志娟 等: "刘瑞芬辨治输卵管性不孕经验", 《辽宁中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567871A (en) * | 2018-01-25 | 2018-09-25 | 徐光亮 | It is a kind of to treat infertile medicine pill |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511689B (en) | 2020-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106334060B (en) | A kind of pharmaceutical composition for treating obese polycystic ovary syndrome | |
| CN101564486A (en) | Medicament for preventing and treating ruminant post-natal diseases and preparation method thereof | |
| CN103251859A (en) | Pharmaceutical composition for treating dermatopathy | |
| CN106511689A (en) | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type fallopian tube blockage | |
| CN102225118B (en) | Blood-activating wind-dispelling liquid | |
| CN101966278B (en) | Traditional Chinese medicine for treating urinary tract infection and preparation method thereof | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN106729327B (en) | Traditional Chinese medicine composition for treating qi-blood deficiency and kidney deficiency type irregular menstruation | |
| CN105434739A (en) | Traditional Chinese medicine composition for treating chalazia and preparation method thereof | |
| CN104587389A (en) | Traditional Chinese medicine composition for treating neck shoulder pain and lumbocrural pain | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN103550744A (en) | Pure traditional Chinese medicine preparation for dental ulcers | |
| CN115192667B (en) | A Chinese medicine composition for improving sexual function and its preparation method and application | |
| CN114984160B (en) | Mongolian medicine for treating alcoholic liver disease | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof | |
| CN106511881B (en) | A Chinese medicinal composition for invigorating kidney and preventing miscarriage, and its preparation method | |
| CN104940561A (en) | Traditional Chinese medicine preparation for treating eye diseases and preparing method of traditional Chinese medicine preparation | |
| CN105853796A (en) | Medicine composition for treating habitual abortion | |
| CN101912501B (en) | Medicament for treating ormarthritis and preparation method thereof | |
| CN105920457B (en) | A kind of traditional Chinese medicine composition for treating tubal obstruction | |
| CN111803592A (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application thereof | |
| CN114949134A (en) | Composition for improving live yield of threatened abortion patient and preparation method thereof | |
| CN105031552A (en) | Traditional Chinese medicine composition for treating gynecological tumors | |
| CN104474512A (en) | Traditional Chinese medicine for treating hernia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |